Initial clinical data on Medigene's DC vaccines to be presented at the SITC Conference
(Thomson Reuters ONE) -
Medigene AG /
Initial clinical data on Medigene's DC vaccines to be presented at the SITC
Conference
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 7 November, 2014. Medigene AG (MDG1, Frankfurt, Prime
Standard) announces that two presentations on its antigen-tailored dendritic
cell (DC) vaccines and its T cell receptor- (TCR) modified T cells will be
presented at SITC (Society for Immunotherapy of Cancer) 29th Annual Meeting &
Associated Programs in National Harbor/Washington D.C., USA, on Saturday, 8
November 2014.
The poster entitled "Next generation dendritc cells for immunotherapy of acute
myeloid leukemia" shows initial clinical data collected in a current
investigator initiated phase I/II clinical trial for the treatment of acute
myeloid leukemia (AML) conducted at the Ludwig-Maximilian University Hospital
Großhadern, Munich, in cooperation with Prof. Marion Subklewe and Prof. Wolfgang
Hiddemann.
The abstract is available for download at:
http://www.immunotherapyofcancer.org/content/pdf/2051-1426-2-S3-P84.pdf
The poster entitled "Generation of tumour antigen-specific CD4+ and CD8+ T cells
by simultaneous MHC-I and -II epitope presentation in vitro and in vivo"
outlines parts of Medigene's immunotherapeutic TCR program, particularly the
isolation and identification of tumour specific T cells.
The abstract is available for download at:
http://www.immunotherapyofcancer.org/content/pdf/2051-1426-1-S1-P6.pdf
About Medigene's DC vaccines: The platform for the development of antigen-
tailored DC vaccines is the most advanced platform of the three highly
innovative and complementary immunotherapy platforms of Medigene Immunotherapies
GmbH (formerly Trianta Immunotherapies GmbH), which was recently acquired by
Medigene AG. Currently the DC vaccines are being evaluated in two ongoing
investigator-initiated trials in clinical phases II (prostate cancer) and I/II
(AML, acute myeloid leukaemia). Medigene concentrates on the further development
of DC vaccines in hematological malignancies and plans to initiate a further
clinical study in AML in 2014.
Medigene's dendritic cell product platform allows the design of new generation
dendritic cell vaccines. Dendritic cells can take up antigens efficiently,
process them and present them on their surface in a form that can induce T cells
to divide and mature and thus enable the T cells to attack tumour cells.
Dendritic cells can also induce natural killer cells to become active and attack
tumour cells. Medigene has established new, fast and efficient methods for
preparation of autologous (patient-specific) mature dendritic cells that have
relevant characteristics to activate both T cells and natural killer cells. They
are developed to carry multiple tumour antigens to treat various types of
cancer, suited for treatment of minimal residual disease or use in combination
therapies.
About Medigene's T cell receptor- (TCR) modified T cells: This therapy approach
aims to utilize the body's own machinery - the T cell - to target and destroy
cancer by arming normal patient-derived T cells with new T cell receptors that
enable them to detect and efficiently kill tumour cells. This form of
immunotherapy is designed to overcome a patient's tolerance to cancer since the
T cells of the patient are activated and modified outside the body, away from
generalized immune suppression in the patient. Compared to small molecule or
antibody based therapies this approach can be used for new targets to fight
tumours. A large army of specific T cells is made available to patients within a
short period of time. The therapy is potentially suited for the treatment of
advanced cancer.
Currently, a comprehensive library of recombinant T-cell receptors and a GMP-
compliant process for their combination with patient-derived T cells is being
established. Discussions with regulatory authorities for the preparation of
first clinical trials with defined product candidates are ongoing.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. Medigene concentrates
on the development of personalized T cell immunotherapies with a focus on
haematological malignancies. Medigene is the first German biotech company to
have revenues from a marketed product, which is distributed by commercial
partner companies. Medigene has advanced drug candidates which are licensed to
partners and additional candidates in clinical development. The company is
developing highly innovative treatment platforms concentrating on cancer and
autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) is a registered trademark of Medigene AG. These trademark may be
owned or licensed in select locations only.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please visit:
http://www.medigene.de/unsubscribe
Press release as PDF :
http://hugin.info/132073/R/1869942/657576.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#1869942]
Unternehmensinformation / Kurzprofil:
Datum: 07.11.2014 - 18:00 Uhr
Sprache: Deutsch
News-ID 350822
Anzahl Zeichen: 6843
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 188 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Initial clinical data on Medigene's DC vaccines to be presented at the SITC Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
